Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IL-2-activated cord blood mononuclear cells.

S Derzic1, V Slone, L Sender

  • 1Children's Hospital of Orange County Research Institute, Orange, California 91006, USA.

Cytotherapy
|October 21, 2005
PubMed
Summary

Interleukin-2 (IL-2)-activated cord blood (CB) cells show potent anti-leukemia activity. Eight-day maturation of CB mononuclear cells (MNC) with IL-2 enhances cytotoxic cell populations and cytokine production for potential immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychological adjustment of children in the pretransplant phase of bone marrow transplantation: Relationships with parent distress, parent stress, and child coping.

Journal of clinical psychology in medical settings·2013
Same author

Metastatic Ewing's Sarcoma to the Right Ventricle.

Images in paediatric cardiology·2012
Same author

Chemotherapy and donor leukocyte infusions for relapsed juvenile myelomonocytic leukemia (JMML).

Bone marrow transplantation·2004
Same author

Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.

Bone marrow transplantation·1999
Same author

Cord Blood Transplantation Study (COBLT): cord blood bank standard operating procedures.

Journal of hematotherapy·1999
Same author

Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies.

Medical and pediatric oncology·1997

Area of Science:

  • Immunology
  • Hematology
  • Cell Biology

Background:

  • Cord blood (CB) research highlights the potential of IL-2-activated CB for eradicating minimal residual disease post-hematopoietic stem cell transplantation.
  • This immunotherapy approach requires further pre-clinical investigation using human hematologic malignancy models.

Purpose of the Study:

  • To compare the anti-tumor efficacy of IL-2-matured CB mononuclear cells (MNC) against bone marrow (BM) cells.
  • To characterize the phenotype and cytokine secretion of IL-2 CB MNC during peak anti-leukemia cytotoxic activity.

Main Methods:

  • Phenotypic analysis using flow cytometry.
  • Cytokine secretion assessment via ELISA.
  • Cytotoxic activity evaluation using cytotoxicity assays.

Related Experiment Videos

Main Results:

  • IL-2 maturation significantly altered CB MNC phenotype, increasing CD8+, CD16+ CD56+, CD56+, and CD56+ CD8+ populations after 8 days.
  • Novel CD8+ CD56+ cells emerged in IL-2-stimulated CB MNC.
  • Elevated levels of INF-gamma, TNF-alpha, and GM-SCF were observed, alongside potent lytic activity against tumor targets.

Conclusions:

  • Eight-day IL-2 CB MNC cultures peak with increased cytotoxic cells and cytokines, suggesting therapeutic potential.
  • Culture duration is critical for optimizing CB IL-2 applications in transplantation to enhance graft-versus-leukemia (GvL) effects.